Literature DB >> 14633716

Free and N-(2-hydroxypropyl)methacrylamide copolymer-bound geldanamycin derivative induce different stress responses in A2780 human ovarian carcinoma cells.

Nobuhiro Nishiyama1, Aparna Nori, Alexander Malugin, Yuji Kasuya, Pavla Kopecková, Jindrich Kopecek.   

Abstract

The effects of geldanamycin (GA), 17-(3-aminopropylamino)-17-demethoxygeldanamycin (AP-GA), and N-(2-hydroxypropyl)methacrylamide copolymer-AP-GA conjugate [P(AP-GA)] on A2780 human ovarian carcinoma cells at an equitoxic dose (2x IC(50)) were compared by the gene expression array analysis. All treatments resulted in similar gene expression profiles up to 12 h (e.g., down-regulation of CDK4 and up-regulation of APAF-1), although P(AP-GA)-treated cells showed delayed gene expression because of time-dependent internalization of the conjugate and intracellular drug release from P(AP-GA). However, AP-GA-treated cells showed elevated expression of HSP70 and HSP27 after 6 h compared with that observed by GA and P(AP-GA) treatments. Depletion of C-Raf, an HSP90 client protein, was observed in all treatments up to 12 h. Confocal microscopy using mesochlorin e(6) as a model drug revealed that drug release caused by the lysosomal cleavage of glycylphenylalanylleucylglycine oligopeptide spacer, used as GA derivative copolymer attachment/release point, was moderately fast. These results suggested that AP-GA treatment may activate stress-response pathways, whereas P(AP-GA) treatment may suppress them and trigger signaling pathways essential to cell growth arrest and death by inducing an HSP90-active factor. Although GA and P(AP-GA) treatments induced a time-dependent increase in HSP70 and HSP27 protein expression (detected by Western blotting analysis), AP-GA treatment resulted in more rapid and more intense expression of both proteins. Our results suggest that conjugation of AP-GA to N-(2-hydroxypropyl)methacrylamide copolymer may be able to modulate the cell stress responses induced by AP-GA because of differences in its internalization mechanism, subcellular localization, and intracellular concentration gradients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14633716

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Selective inhibitory effect of HPMA copolymer-cyclopamine conjugate on prostate cancer stem cells.

Authors:  Yan Zhou; Jiyuan Yang; Jindřich Kopeček
Journal:  Biomaterials       Date:  2011-12-03       Impact factor: 12.479

2.  Medicinal facilities to B16F10 melanoma cells for distant metastasis control with a supramolecular complex by DEAE-dextran-MMA copolymer/paclitaxel.

Authors:  Yuki Eshita; Rui-Cheng Ji; Masayasu Onishi; Takashi Kobayashi; Masaaki Mizuno; Jun Yoshida; Naoji Kubota; Yasuhiko Onishi
Journal:  Drug Deliv Transl Res       Date:  2015-02       Impact factor: 4.617

3.  Biomaterials and drug delivery: past, present, and future.

Authors:  Jindrich Kopecek
Journal:  Mol Pharm       Date:  2010-08-02       Impact factor: 4.939

4.  Delivery of HSP90 Inhibitor Using Water Soluble Polymeric Conjugates with High Drug Payload.

Authors:  Jose A Suárez Del Pino; Rohit Kolhatkar
Journal:  Pharm Res       Date:  2017-09-14       Impact factor: 4.200

Review 5.  Biological rationale for the design of polymeric anti-cancer nanomedicines.

Authors:  Yan Zhou; Jindřich Kopeček
Journal:  J Drug Target       Date:  2012-09-26       Impact factor: 5.121

6.  Enhanced antitumor activity of combinations of free and HPMA copolymer-bound drugs.

Authors:  J Hongrapipat; P Kopecková; S Prakongpan; J Kopecek
Journal:  Int J Pharm       Date:  2007-09-22       Impact factor: 5.875

Review 7.  Polymer-drug conjugates: origins, progress to date and future directions.

Authors:  Jindřich Kopeček
Journal:  Adv Drug Deliv Rev       Date:  2012-11-02       Impact factor: 15.470

8.  HPMA copolymers: origins, early developments, present, and future.

Authors:  Jindrich Kopecek; Pavla Kopecková
Journal:  Adv Drug Deliv Rev       Date:  2009-11-14       Impact factor: 15.470

Review 9.  Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review).

Authors:  Yan-Jun Zhong; Li-Hua Shao; Yan Li
Journal:  Int J Oncol       Date:  2012-12-28       Impact factor: 5.650

Review 10.  Anticancer efficacy of a supramolecular complex of a 2-diethylaminoethyl-dextran-MMA graft copolymer and paclitaxel used as an artificial enzyme.

Authors:  Yasuhiko Onishi; Yuki Eshita; Rui-Cheng Ji; Masayasu Onishi; Takashi Kobayashi; Masaaki Mizuno; Jun Yoshida; Naoji Kubota
Journal:  Beilstein J Nanotechnol       Date:  2014-12-01       Impact factor: 3.649

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.